Home / Stocks / Thyrocare Tech Ltd
THYROCARE

Thyrocare Tech Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹504.85

Change

+1.25 (0.25%)

Open

₹504.0

Prev. Close

₹503.6

Day High

₹513.0

Day Low

₹503.05

Volume Analysis

Traded

155,190

Delivered

79,439

Delivery %

51.19%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (28.4%)
  • •Strong operating margin (32.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (3)

  • •Strong 3-year EPS growth (36.1%)
  • •Strong 3-year revenue growth (16.3%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹520.84 ₹516.92 ₹510.89 ₹506.97 ₹500.94 ₹497.02 ₹490.99
Fibonacci ₹516.92 ₹513.12 ₹510.77 ₹506.97 ₹503.17 ₹500.82 ₹497.02
Camarilla ₹507.59 ₹506.67 ₹505.76 ₹506.97 ₹503.94 ₹503.03 ₹502.11

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+13.02%

1 Week

+3.45%

1 Month

+10.66%

3 Months

-10.73%

6 Months

+8.37%

1 Year

-66.9%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹89.54

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

22.97%

Net margin 15.38% × asset turnover 1.14x × equity multiplier 1.31x

Company Overview

Sector

Healthcare

Market Cap

₹7,940 Cr

P/E (TTM)

45.3

ROE

28.4%

Book Value

₹34.8

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Thyrocare Tech Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 66/100. The strongest factor is Financial Strength (100/100), while Valuation (7/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (28.4%); strong operating margin (32.0%); promoter holding is falling. Strong 3-year EPS growth (36.1%).

TopFund Score — Fundamentals Quality

66/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

68

Valuation

7

Cash Flow

99

Corporate Governance

43

Momentum

49

Institutional Ownership

76

Business Quality

95

Risk & Volatility

25

Liquidity

51

From Screener.in

  • +Company has been maintaining a healthy dividend payout of 131%
  • −Stock is trading at 14.3 times its book value
  • −Promoter holding has decreased over last quarter: -9.90%

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Chief Scientific Officer Dr. Preet Kaur resigns; last working day November 6, 2026.

Please find attached the Earnings Call Transcript held on October 29, 2026

Please find attached herewith Newspaper Publication of Unaudited Financial Results for the quarter and half year ended on September 30, 2026

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 148 135 154 157 177 166 187 193 217 196 224 240 271
Expenses + 110 103 121 115 129 124 130 135 145 138 149 163 182
Operating Profit 38 32 34 42 48 42 57 58 71 58 75 77 89
OPM % 25.0% 23.0% 22.0% 27.0% 27.0% 25.0% 30.0% 30.0% 33.0% 30.0% 34.0% 32.0% 33.0%
Other Income + 3 3 3 4 3 4 5 5 3 -1 5 5 -41
Interest 1 1 1 1 1 1 1 1 1 0 2 1 2
Depreciation 11 13 13 11 13 17 14 11 12 22 14 12 14
Profit before tax 28 20 23 34 37 28 47 50 63 35 64 68 34
Tax % 28.0% 26.0% 25.0% 29.0% 28.0% 32.0% 54.0% 24.0% 24.0% 21.0% 24.0% 25.0% 55.0%
Net Profit + 20 15 17 24 26 19 22 38 48 28 49 51 15
EPS in Rs 1 1 1 2 2 1 1 2 3 2 3 3 1
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 10 5 14 16 20 23 21 23 22 18 20 24 25

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 183 241 304 356 403 434 495 589 527 572 687 829 930
Expenses + 110 147 189 212 249 261 323 353 403 432 498 566 631
Operating Profit 73 94 115 145 154 174 171 236 123 140 190 263 299
OPM % 40.0% 39.0% 38.0% 41.0% 38.0% 40.0% 35.0% 40.0% 23.0% 24.0% 28.0% 32.0% 32.0%
Other Income + 8 7 -15 21 11 1 12 29 9 9 15 12 -32
Interest 0 1 0 0 1 2 1 3 5 6 4 4 4
Depreciation 13 18 18 20 26 32 30 34 39 47 55 59 62
Profit before tax 68 82 82 145 138 140 152 228 89 96 145 213 202
Tax % 35.0% 37.0% 48.0% 36.0% 38.0% 37.0% 26.0% 23.0% 27.0% 28.0% 38.0% 24.0% —
Net Profit + 44 52 43 93 85 88 113 176 64 69 91 163 143
EPS in Rs 3 3 3 6 5 6 7 11 4 4 6 10 9
Dividend Payout % 171.0% 104.0% 125.0% 58.0% 124.0% 30.0% 117.0% 45.0% 148.0% 135.0% 122.0% 137.0% —
Sales growth — 32 26 17 13 8 14 19 -11 9 20 21 22

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 226 312 354 390 382 314 374 474 481 474 494 426 394
Borrowings + 0 0 0 0 2 12 8 21 23 42 25 51 57
Other Liabilities + 53 44 30 36 37 90 106 60 74 75 121 111 115
Total Liabilities 329 410 438 479 475 469 541 607 632 644 693 747 725
Fixed Assets + 196 259 259 299 294 269 253 285 294 306 297 317 289
CWIP 6 1 17 0 1 5 8 3 2 3 14 3 1
Investments 86 93 104 120 95 90 126 146 144 162 162 177 168
Other Assets + 42 56 58 60 84 105 154 173 192 173 220 250 267
Total Assets 329 410 438 479 475 469 541 607 632 644 693 747 725
Equity Capital 51 54 54 54 53 53 53 53 53 53 53 159 159

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 34 68 90 107 100 168 115 113 129 168 191 213
Cash from Investing Activity + -18 -18 -42 -43 -12 1 -49 -24 -39 -91 -53 -23
Cash from Financing Activity + -23 -45 -49 -64 -94 -165 -62 -89 -86 -85 -130 -170
Net Cash Flow -6 5 0 0 -5 4 4 0 4 -8 8 21
Free Cash Flow 25 53 53 63 61 158 93 99 88 107 146 198
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 79 106 113 108 104 122 92 72 128 141 123 104

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 71.11% → 51.02%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 11.64% 11.11% 11.49% 12.15% 11.49% 11.57% 11.18% 10.61% 13.61% 12.71% 12.71% 13.69%
Promoters 71.11% 71.11% 71.11% 71.11% 71.06% 71.06% 71.06% 71.06% 60.93% 60.92% 60.92% 51.02%
FII 3.35% 2.9% 2.49% 1.93% 2.77% 2.41% 3.23% 4.85% 4.96% 5.37% 5.43% 9.37%
DII 13.89% 14.88% 14.89% 14.79% 14.68% 14.97% 14.54% 13.47% 20.52% 21.0% 20.92% 25.92%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Thyrocare Tech Ltd (this stock) 7,940 45.3 14.31 28.4%
Suven Life Sciences Ltd 7,850 — 17.38 -81.5%
Sanofi India Limited 7,603 17.2 8.83 47.1%
Healthcare Glob. Ent. Ltd 8,562 216.0 6.36 2.54%
Kovai Medical Center & Ho 7,108 123.0 24.58 22.2%
Bliss Gvs Pharma Ltd 7,075 43.5 5.5 11.8%
Sun Pharma Adv.res.co.ltd 6,680 4.05 4.64 279.0%

Which Mutual Funds Hold Thyrocare Tech Ltd?

Frequently Asked Questions about Thyrocare Tech Ltd

Community Sentiment

What are other investors saying about Thyrocare Tech Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.